key: cord-0993089-cax9xxl4
authors: Li, Xianghui; Zhang, Yabo; He, Libing; Si, Jiangzhe; Qiu, Shuai; He, Yuhua; Wei, Jiacun; Wang, Zhili; Xie, Longxiang; Li, Yanzhang; Teng, Tieshan
title: Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic
date: 2022-02-14
journal: Int J Biol Sci
DOI: 10.7150/ijbs.66369
sha: 3458a7ed47e94ca92e62b0a367fb60d6487523ac
doc_id: 993089
cord_uid: cax9xxl4

Following onset of the first recorded case of Coronavirus disease 2019 (COVID-19) in December 2019, more than 269 million cases and over 5.3 million deaths have been confirmed worldwide. COVID-19 is a highly infectious pneumonia, caused by a novel virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, it poses a severe threat to human health across the globe, a trend that is likely to persist in the foreseeable future. This paper reviews SARS-CoV-2 immunity, the latest development of anti-SARS-CoV-2 drugs as well as exploring in detail, immune escape induced by SARS-CoV-2. We expect that the findings will provide a basis for COVID-19 prevention and treatment.

In December 2019, China reported a few cases of acute atypical respiratory disease in Wuhan, which rapidly spreads across the country. On February 11, 2020, World Health Organization (WHO) nominated the acute respiratory infectious disease "COVID-19" [1] , while the International Committee on Taxonomy of Viruses (ICTV) immediately named this virus isolate "SARS-CoV-2". Coronavirus, a spherical or polymorphic RNA virus, contains a single-stranded sense RNA genome and is the longest RNA virus so far reported [2] . According to the systematic classification of viruses, coronavirus is part of Coronaviridae genus, the order Nidovirales, and can be further grouped into four genera, α, β, γ and δ based on their genome sequence homology [3] . As a large family of viruses, coronavirus specifically is associated with common flu and severe infection. Previously, seven coronaviruses had been reported to cause human respiratory diseases [4] , including NL63, human coronavirus 229E, HKU1, and OC43, which specifically infect the upper respiratory tract with mild symptoms [5] . The other three coronaviruses include the Middle East respiratory syndrome (MERS-CoV), severe acute respiratory syndrome (SARS-CoV), and the recent SARS-CoV-2, which are capable of infecting the lower respiratory tract, as well as may bring about fatal pneumonia. SARS-CoV-2 represents different similarities to SARS-CoV (79%), bat coronavirus RaTG13 (96.2%), and pangolin coronavirus (92.4%) [6, 7] . Herein, we explore immune reaction of SARS-CoV-2 infection together with the latest development of antiviral drugs in view of the recently published literature.

SARS-CoV-2 invades the host cell where it undergoes massive proliferation. Consequently, the cell lyses, and then releases virus particles and intracellular components. The pattern recognition receptors (PRRs) in innate immune cells trigger the inducible response of innate immune system as soon as they recognize the virus particles and intracellular components [8] . However, SARS-CoV-2 is also able to avoid or delay the stimulation of type I IFN-related response in vivo.

The spike protein of SARS-CoV-2 mediates major entry steps: including receptor binding and membrane fusion. Furin and TMPRSS2 are the two major proteases involved in viral attachment and membrane fusion [9] . Furin, a ubiquitous proprotein convertase in the surface of Golgi apparatus, is capable of cleaving S protein into S1 and S2 subunits for virus maturation. Therefore, the S protein of the mature SARS-CoV-2 is comprised of two non-covalently subunits: the S1 subunit binds the ACE2 receptor and the S2 subunit anchors the S protein to the virion membrane and mediates membrane fusion. ACE2 engagement by SARS-CoV-2 will exposes an additional cleavage site in S2 subunits, termed S2' site. The S2' site can be cleaved by TMPRSS2 on the cell surface or cathepsin L in the endosomal compartment following ACE2-mediated endocytosis to release the fusion peptide and then initiate fusion pore formation, which allows the SARS-CoV-2 genome to reach the cytoplasm.

Although SARS-CoV-2 utilize ACE2 as the main receptor for cell entry, cells in the main target organs including the lungs and bronchi display low levels of ACE2 expression. Moreover, SARS-CoV-2 can also efficiently infect the upper respiratory tract and other tissues/organs, including the pharynx, heart, liver, brain, kidneys, and the gastrointestinal tract. These results suggest that SARS-CoV-2 employs other receptors for colonization and entry [10] [11] [12] . Recent studies have demonstrated that a few cell surface molecules consisting of AXL, KREMEN1, CD147, KIM-1, TfR and DPP4 also are potential alternative receptor independent of ACE2. Meanwhile, heparan sulfate, GRP78, lectin and neuropilin-1 are considered as auxiliary attachment receptors dependent on ACE2 ( Table 1) .

Following the human infected by SARS-CoV-2, virus genomic RNA or the intermediate product of virus replication (dsRNA) is recognized by the immune system via pattern recognition receptors (PRRs) [28] . In PRRs, toll-like receptors (TLRs), RIG-I-like receptors (RLRs), for instance, melanoma differentiation-associated protein 5 (MDA5), and retinoic acid-induced gene protein I (RIG-I) are crucial in viral RNA recognition [29] . Subsequently, the activated receptors cause a cascade of downstream immune signals, including IRF3/7 activation and nuclear translocation of NF-κB (nuclear factor kappa B), which thus can induce the expression of interferon (IFN), proinflammatory cytokines and chemokines, etc. (Figure 1 ) [30] . The chemokines mentioned above are important mediators for giving rise to the release of innate immune cells from the bone marrow tissue. Proteolysis of S protein at the S1/S2 and S2′ sites [27] Cellular innate immune response to SARS-CoV-2 SARS-CoV-2 infection of the human lung triggers lung inflammatory innate immune response, which results in the recruitment of innate immune cells including monocytes, neutrophils, NK cells, DCs to the lungs. These innate immune cells are capable of releasing cytokines and prime adaptive T and B cell immune responses.

Phenotypic studies of infiltrating monocytes in the bronchoalveolar lavage (BAL) of COVID-19 patients have revealed that a surge of CD169 + monocytes and depletion of CD16 + CD14monocytes were observed early after symptom onset [31, 32] . CD169 + monocytes have a strong association with proinflammatory cytokines, including IFN-γ, MCP-2, IL-18 and IL-6 [32] . At later stages, CD16 + monocytes were present in patients with severe disease, dominated by high CCL3 and CCL4 abundance [32] . In the same way, the high concentration of neutrophil-released NETs (Neutrophil extracellular traps) are detected in COVID-19 patients' tracheal aspirate, which are considered to be related to the COVID-19 severity [33] . SARS-CoV-2-triggered NETs characterized by extracellular exposure of DNA, myeloperoxidase (MPO) and histone, capacity to induce tissue damage and promote systemic immunothrombosis [33, 34] .

It is widely reported that overall NK cell numbers are substantially reduced in the blood of COVID-19 patients relative to healthy controls [31] . NK cells exert anti-viral activity but are functionally impaired with increased IFN-γ and TNF production in severe COVID-19 [35] . Further, NK cell dysfunction may be relevant to the development of fibrotic lung disease, as NK cells exhibited impaired anti-fibrotic activity [35] .

As specialized producers of IFN-I, pDCs can secrete a great quantity of IFN-I isoforms immediately after SARS-CoV-2 infection. Notably, several days after SARS-CoV-2 infection, pDCs tune down their capacity for IFN-I production, which can favor prolonged viral replication and opportunistic secondary infections, termed "pDC exhaustion" [36] . Furthermore, the expression of CD86 and HLA-DR in peripheral mDCs are reduced in severe COVID-19, which are crucial for antigen presentation and the induction of helper T cell response [37] . This result may imply that the decreased DC capacity in response to TLR stimulation is associated to the diminished virus-specific T cell response in severe COVID-19 cases [37] .

Cell transcriptomic profiling demonstrated that SARS-CoV-2 infection result in the activation of alveolar macrophages which promote the production of T cell chemoattractant [38] . Then, T cells recruited can trigger the activation of the adaptor molecule MAVS on the mitochondrial membrane, thus activating TRAF3 upstream of IFN regulatory factors (IRFs) 3/7. In the nucleus, NF-κB up-regulates expression of genes encoding interferon, pro-inflammatory cytokines (IL-1, IL-6, TNF-α, etc.) and chemokines that promote transcription of inflammatory acute phase-related proteins. The tyrosine kinases JAK1 and STAT were activated through the binding of Type I interferon and IFNAR. Activated JAK1/STAT can phosphorylate STAT1 and STAT2 to form heterodimers. ISGF3 is then transferred to the nucleus and initiate interferon-stimulated genes (ISGs) transcription. The ISG-encoded proteins exert antiviral activity by preventing virus invasion, replication, and budding. SARS-CoV-2-encoded proteins (red) inhibit multiple aspects of these pathways, resulting in decreased IFN and altered proinflammatory cytokine expression. by chemokines are capable of inducing the production of IFN-γ, which can in turn stimulate macrophages to produce a large number of inflammatory cytokines and further promote T cell activation [38] . In each new area of infection, positive feedback loop between alveolar macrophages containing the virus and activated T cells could promote persistent injury and inflammation.

Adaptive immune response has been shown to play important roles in the control of almost all viral infections and promoting viral clearance, which consist of three major cell types: CD4 + T cells, CD8 + T cells and B cells. During SARS-CoV-2 infection, initiation of adaptive immune responses (6-10 days) was indispensable for naive cells undergoing proliferation and differentiation into effector cells [39] . Meanwhile, the adaptive immune response will be not triggered by the time of the innate immune activation, which will result in high viral burden [40] and excessive lung immunopathology [41] .

CD4 + T cell immune responses have close relationships with control of mainly SARS-CoV-2 infection more than CD8 + T cells [42] [43] [44] . Among the COVID-19 cases in recovery period, almost all infections caused by SARS-CoV-2 proteins could initiate CD4 + T immune cell responses [42] . And S, M, and N proteins were the most prominent targets of SARS-CoV-2-specific CD4 + T cells. Notably, compared with B and CD8 + T cells, the elevated levels of CD4 + T cells in acute COVID-19 had the strongest association with mild disease and rapid viral clearance [45] . In contrast, rapid reduction of CD4 + T cells was related to severe COVID-19 [46] . T follicular helper cells (Tfh) and Th1 cells are mainly cell subtypes differentiated from CD4 + T cells. Th1 cells exert antiviral activities via IFN-γ production and secretion of cytokines IL-12, IL-3 and IL-2. Further, Th1 cells can induce CTL differentiation and activate B cells to secrete cytokines IL-10, IL-5 and IL-4. Tfh cells are able to assist differentiation of memory B cells and maintain long-lasting humoral immunity which is important for the progress of neutralizing antibody response [47] .

CD8 + T cells have an important role in prevention of viral infections, on account of the availability of eliminating infected cells. In virus infections, the presence of virus-specific CD8 + T cells is closely related with the better outcome of patients with COVID-19 [48] . Several viral antigens consisting of S, N, M and Orf3a can be specifically recognized by SARS-CoV-2 specific CD8 + T cells [49, 50] . In acute COVID-19, viral specific CD8 + T cell responses were activated swiftly, with a study of specific CD8 + T cells as early as the first day after COVID symptom onset [51] . In acute SARS-CoV-2 infection, virus-specific CD8 + T cells indicate high expression of molecules related with potent cytotoxic effector functions consisting of CD107a, perforin, granzyme B and IFN-γ [51] .

Most SARS-CoV-2 infected persons seroconversion occurred were within 5-15 days of PSO, especially about 90% within 10 days of PSO [52] [53] [54] . The main antigens involved in detection of seroconversion in infected individuals are Spike and nucleocapsid proteins [55] . It is relatively easy to synthesis neutralizing antibodies against SARS-CoV-2 by many B cells with little affinity maturation required [56] [57] [58] [59] . There is a positive correlation between neutralizing-antibody titers and COVID-19 disease severity in large-scale cohort studies [60] . Both SARS-CoV and MERS share the similar observations [61] . After infection, the adaptive immune response occurs late, and many host cells are actually infected until an antibody response develops. This may be why the titer of SARS-CoV-2 neutralizing antibody is not associated with the reduction of disease severity in primary COVID-19 [62] .

Severe COVID-19 is usually associated to a dysregulated innate immune response, which is widely characterized by a delayed IFN response relative to peak virus replication and an excessive inflammatory response. After SARS-CoV-2 invasion, timely activation of IFN-I is critical for suppression of viral replication [63] . Notably, SARS-CoV-2 produces a variety of effector molecules, including structural proteins, non-structural proteins and accessory proteins (Table 1) , which selectively counteract the IFN response, thereby evading the immune system [31] . Although the specific molecular mechanisms remain to be determined, suppression of the IFN-I is considered to occur at several stages consisting of inhibiting the PRR recognition of SARS-CoV-2 RNA and preventing translation via degradation of host cell mRNA [64] . The resultant suppressed or delayed IFN-I cascade enhances viral replication and causes inflammatory cytokine storm [65] . Recent study found that cytokine profiles from COVID-19 patients with cytokine storm syndrome (CSS) were linked to lung damage, multi-organ failure, and a hostile prognosis in serious COVID-19 patients [66, 67] .

Based on the strong association between the increased cytokine levels and severity of COVID-19, modulation of inflammatory cytokines provides therapy strategies to mitigate severe disease. Cytokine-targeted therapies have become the preferable option as they have fewer potential adverse effects compared to conventional antiviral therapy, for instance JAK/STAT inhibitors, IL-1R inhibitors and IL-6R inhibitors [68, 69] .

No specific drug is available for COVID-19 cure based on the current understanding of the pathophysiology [86] . The drug treatment options mainly focus on broad-spectrum antiviral drugs, membrane fusion inhibitors, protease inhibitors, virus spike protein targeted drugs, and immune modulators, etc. [87, 88] . These drugs can prevent the virus interaction with the host cell receptor, or inhibit virus replication as well as excessive antiviral immune responses. Several potential anti-SARS-CoV-2 drugs are currently in clinical trials with different phases (Figure 2 ). 

Nucleoside analogues, such as remdesivir (GS-5734) [89] , favipiravir [90] and ribavirin [91] are presently considered as potential drug candidates for the treatment of COVID-19. All these drugs are available for blocking viral RNA-dependent RNA polymerase (RdRp) during RNA synthesis, as a mechanism to block virus replication [92] . Remdesivir, a broad-spectrum anti-virus' drug, was originally used for the treatment of Ebola and Marburg virus infections. And several animal studies have indicated that it is highly effective against the coronaviruses [93] . A clinical study revealed that remdesivir exerts anti-virus activity against SARS-CoV-2 through in vitro and in vivo test [94, 95] . Preliminary results of clinical trials showed that remdesivir could shorten the recovery time of COVID-19 patients by a couple of days compared to placebo, with no significant difference in mortality [96] [97] [98] . FDA has authorized remdesivir for emergency use in severe COVID-19 cases [99] . However, some international phase III clinical trials are currently evaluating the safety and efficacy of remdesivir for COVID-19 management. Favipiravir (T-705), an antiviral drug developed in Japan, has been approved in China, Russia, and India for COVID-19 treatment [100] . A clinical study in China suggested that favipiravir significantly decreased the signs on chest imaging and shortened the time interval of virus infection [101] . Moreover, a preliminary report from Japan showed that mild COVID-19 patients exhibited clinical improvement rates on the 7 th and 14 th day being 73.8% and 87.8%, respectively [102] . Similarly, for severe COVID-19 patients, the clinical improvement rates on the 7 th and 14 th day were 40.1% and 60.3%, respectively [103] . Also, there are several clinical trials on ribavirin for use in COVID-19 treatment. Although ribavirin has received extensive application in coronavirus treatment, it is associated with adverse reactions; therefore, it should be used with caution [104] .

Human transmembrane protease-serine 2 (TMPRSS2) is an essential host cell protease for SARS-CoV-2 spike protein activation [105] . Camostat mesylate, an effective inhibitor of TMPRSS2, is currently under investigation for its effectiveness in COVID-19 patients. A possible advantage of blocking a critical host component like TMPRSS2 rather than targeting the virus itself is that its effect is not likely to be negated by mutations in the virus genome [106] . Camostat mesylate is available for blocking SARS-CoV invasion and protects mice from lethal infection via inhibiting TMPRSS2 [107] . Recently, Clinical observation demonstrated that Camostat mesylate blocked SARS-CoV-2 entry into human lung cells [108] . In addition, a few animal trials have exhibited that the treatment of SARS-CoV-2-infected mice with a therapeutic dose of Camostat mesylate can reduce the mortality of mice from 100% to 35% [109] . Furthermore, these studies also revealed that Camostat mesylate reduces TGF-β levels which would alleviate COVID-19-induced acute respiratory distress syndrome (ARDS). Obviously, as a potential antiviral drug against SARS-CoV-2 infection, sufficient clinical data are still needed to support its efficacy.

Baricitinib, often used to treat rheumatoid arthritis previously, was urgently approved by FDA to be used in combination with remdesivir in the treatment of patients with COVID-19 in November19, 2020. Baricitinib is available for inhibiting SARS-CoV-2 entry into target cells via preventing AP2-associated protein kinase 1(AAK1) and cyclin G-related kinase (GAK) activation [110] [111] [112] . Moreover, Baricitinib is also available for reducing IL-6 levels and down-regulating CD80/CD86 expression in human monocyte, thereby impeding the release of type I IFN [113, 114] . Collectively, Baricitinib can prevent cytokine storm syndrome via inhibiting the release of these cytokines, demonstrating that Baricitinib could be essential at every viral infection stage. Ultimately, the virus entry into cells in the early stage is reduced and then exerts anti-inflammatory effects in the late period [115] .

A large number of studies have shown that renin-angiotensin system (RAS) deregulation is responsible for ARDS, which is the main clinical manifestation of severe COVID-19. Although excessive angiotensin II is responsible for the exacerbation of COVID-19, yet the reduction of angiotensin II or blocking RAS pathway is able to limit the severity of acute lung injury caused by SARS-CoV-2 infection. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are considered to exert inhibition effects on the renin-angiotensin system (RAS) [116] . Zhang et al found that the mortality of COVID-19 sufferers treated with ACEIs/ARBs was much lower than those treated without ACEIs/ARBs [117] .

Several clinical trials have also demonstrated that the up-regulation ACE2 expression levels induced by ARBs and ACEIs are supposed to reduce lung injury in SARS-CoV-2 infection presumably via decreasing ACE-derived Ang II [118, 119] . While several organizations have issued statements advising the continuation of treatment of COVID-19 with ACEIs/ARBs, more large-scale clinical studies are still warranted to elucidate whether it could be associated with other unknown damages to the human body [120] .

Umifenovir (arbidol), a derivative of indole carboxylic acids used for the treatment of influenza A and B virus infection, has been applied to in the treatment of SARS-CoV-2 infections [121] . Umifenovir was available for inhibiting the interaction of S protein with ACE2 via incorporating into cell membranes and disturbing with the hydrogen bonding network of phospholipids, which blocks the membrane fusion of the virus. A study determined that Umifenovir monotherapy was superior to Liponavir/Ritonavir against COVID-19 [122] . COVID-19 patients treated with Umifenovir and Liponavir/ritonavir exhibited better prognosis compared with patients treated with Liponavir/ Ritonavir alone [123] . Paradoxically, a clinical study in Wuhan revealed that Umfenovir did not increase the clearance rate of SARS-CoV-2 or accelerate the recovery of patients in any way [124] . Thereby, the effect of Umfenovir in the treatment of SARS-CoV-2 needs further clinical study.

Abnormally high levels of IL-6 are an indicator of poor outcome in COVID-19 patients with pneumonia and ARDS. Anti-IL-6 biological drugs, such as tocilizumab and sarilumab, have recently been adopted to treat COVID-19 patients with pneumonia [125, 126] . Tocilizumab is a recombinant humanized anti-human IL-6 receptor monoclonal antibody which is capable of blocking the membrane-bound IL-6 receptor (mIL6R), thereby inhibiting signal transduction [127] . COVID-19 patients treated with tocilizumab showed significant fever reduction within several days, and 75% patients were observed a reduced oxygen requirement [128] . Another IL-6 receptor antagonist, sarilumab, may potentially prevent cytokine release syndrome (CRS) and pulmonary symptoms in severe COVID-19 patients [93] . The efficacy and safety of sarilumab in the treatment of hospitalized patients with COVID-19 were evaluated in a randomized, double-blind study, which illustrated that sarilumab was effective in critical COVID-19 patients, but not in severe patients [129] .

Anakinra is a recombinant non-glycosylated human IL-1 receptor antagonist [130, 131] . It is initially approved for the treatment of auto-inflammatory disorders characterized by excess cytokines production which sharing clinical and molecular characteristics with COVID-19 hyperinflammation [132, 133] . Thus, anakinra was used to test the clinical efficacy of treatment in critical COVID-19 patients. Gilles Hayem et al found that anakinra treatment prominently decreased the mortality of severe COVID-19 patients [130] . Another research has also demonstrated that the early administration of anakinra significantly diminished the requirement for invasive mechanical ventilation in COVID-19 ICU patients [93] . Also, preliminary findings of Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial exhibited that anakinra combined with corticosteroids in COVID-19 treatment is more efficacious than the single use [134] .

N-acetylcysteine (NAC) is an L-cysteine precursor which directly scavenges free radicals, especially reactive oxygen species (ROS) [135] . In vivo and in vitro, NAC has been successfully adopted to manage numerous diseases, including chronic inflammation, acetaminophen poisoning and asthma [136] . For COVID-19 infection, NAC was demonstrated to decrease inflammatory cytokines serum levels significantly. Furthermore, NAC can elevate the level of glutathione (GSH) in human T cells and prevent the T lymphocytes apoptosis induced by virus infection [132] . In a randomized trial, ventilator associated pneumonia (VAP) patients related to COVID-19 treated with NAC had a shorter duration of hospital stay and a higher incidence of full restoration. NAC may alleviate insulin resistance by vitamin D deficiency, revealing NAC's potential benefit for diabetics with COVID-19 disease [137] . The adverse effects are uncommon including hypersensitivity reactions, pyrexia and low blood pressure [138, 139] .

Intravenous immunoglobulins (IVIGs) are polyclonal IgG antibodies from the plasma of SARS-CoV-2-infected blood donors [140] . They potentially regulate systemic inflammation via capturing the activated complement factors, blocking the Fc γ-receptors and inhibiting lymphocyte differentiation and activation. Several studies showed that the transition from early to late course of COVID-19 is accompanied by the raised immunoglobulin levels, which indicating that IVIG therapy might be conducive to COVID-19 patients' rehabilitation [141, 142] . In another clinical study, treatment with IVIG for COVID-19 pneumonia within 48 h reduced ventilator days and shortened ICU and hospital length of stay, eventually decreased 28-day mortality [143] . An open randomized clinical trial indicated that adjuvant IVIG therapy was associated with a significantly shorter median time to real-time polymerase chain reaction negativity compared to standard of care (7 vs. 18 days) [144] . Collectively, higher titer polyclonal immunoglobulins from the plasma of convalescent patients and neutralizing antibodies from lung lavage fluid of severe COVID-19 patients are potentially new treatment options in the management of COVID-19 [145] .

Interferon type I can induce the expression of various interferon stimulating genes (ISGs) through the JAK-STAT pathway which interferes with every virus replication step [73] . Previous studies have reported that IFN-I could be an appealing option for SARS-CoV treatment [146] . In vitro, study of experimental data indicated that the sensitivity of SARS-CoV-2 to IFN-I is higher than SARS-CoV. Several studies exhibited that the joint application of nebulized IFN-α2b, corticosteroids and lopinavir/ ritonavir decrease mortality rate to zero in COVID-19 patients. A study involving about 100 COVID-19 patients exhibited that IFN inhalation was very effective in treating SARS-CoV-2 infection, lowing the risk of developing severe disease by 79% [147] . These observations support the option for the emergency application of IFN-I to treat the early COVID-19 pandemic [148] .

Mesenchymal stem cells (MSCs) are pluripotent stem self-renewed cells, also known as adult stem cells. In regenerative medicine, they can improve impaired tissues and organs by differentiating into mature cells to release various cytokines [149, 150] . Lately, Leng et al discovered that MSCs graft improved lung function in COVID-19 patients with pneumonia [151] via decreasing the number of inflammatory cells and elevating the level of lymphocytes [152] . Intravenous transplantation of hUC-MSCs for the treatment of severe COVID-19 exhibited that the 28-day mortality rate in the hUC-MSC treatment group was 0, whereas 10.34% in the control group [153] . Meanwhile, MSC-derived exosomes were tested clinically for treatment of COVID-19 patients and the results showed that 71% of the patients recovered [154, 155] . In addition, MSC-derived exosomes also exhibited prominent amelioration in neutrophil as well as CD4 + and CD8 + lymphocyte numbers, with a decline in C-reactive protein (CRP) and Ferritin [153] . Based on the existed evidence, MSC and its exosomes appear to be an appropriate option for treating patients with COVID-19 pneumonia [156, 157] .

Following SARS-CoV-2 invasion, type II alveolar epithelial cells release inflammatory signals to recruit leukocytes, resulting in a "cytokine storm". Corticosteroids can decrease capillary permeability and reduce leukocyte migration to inflammatory sites [158] . Moreover, it can inhibit neutrophil apoptosis and aggregation [159] . Dexamethasone and methylprednisolone are synthetic corticosteroids [160] , and both can inhibit the transcription activation of pro-inflammatory cytokines and cell adhesion genes with an anti-inflammatory effect. In moderate to severe COVID-19 patients, methylprednisolone treatment with a short course significantly reduced escalation of care from ward to ICU [161] . Surprisingly, a preliminary report from the United Kingdom showed that dexamethasone treatment is only beneficial to the survival of patients with severe COVID-19 requiring respiratory support, but not mild COVID-19 patients who do not require respiratory support.

In two other Brazilian studies, dexamethasone or methylprednisolone treatment conferred survival benefits to hospitalized patients with moderate to severe acute respiratory distress syndrome or over 60 years of age [162] . However, early pulse dose therapy or long-term use of high-dose corticosteroids may be related to delayed virus clearance and high mortality [163] . Therefore, it is imperative to use low doses of corticosteroids in accordance with the severity and clinical indications of COVID-19 patients.

Several evidences suggest that hospitalized COVID-19 patients often suffer from an acute infection-related coagulopathy and elevated risks of microvascular thrombosis [164] . Strategies to prevent thrombosis are of critical importance for reducing the high mortality rate in COVID-19 [165] . Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, and dipyridamole, both of which also possess pleiotropic antiinflammatory or antiviral effects [164, 166] .

Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH), were mostly used for anticoagulant therapy related to SARS-CoV-2 infection [164, 167] . Compared to COVID-19 patients treated with high-dose of LMWH, the mortality of hospitalized patients who did not received any anticoagulant treatment or received low-dose LMWH, was 6.2-fold and 2.0-fold increased, respectively [168] . Also, there is general agreement that thromboprophylaxis should be administered to all hospitalized patients with COVID-19 infection with the use of standard dose of UFH or LMWH [169] .

Dipyridamole (DIP), an antiplatelet agent, is often used for thromboprophylaxis combined with vitamin K antagonists following mechanical heart valve replacement [170] . Previous study regarding coagulation function exhibited that the higher levels of D-dimer was presented in severe COVID-19 patients, becoming more significant with disease progression [171] .In analysis of 12 cases of COVID-19 patients with prophylactic anti-coagulation therapy, it was found that DIP treatment was related to significantly diminished D-dimer levels in comparison to control groups [166] . Half a month after initiation of DIP supplementation, 3 of the 6 severe COVID-19 patients and all 4 of the mild COVID-19 patients were discharged from the hospital [166] .

COVID-19 is the third most deadly human coronavirus disease. While its mortality rate is lower than SARS-CoV and the MERS, COVID-19 is highly infectious and poses threat to global health in this century. More than one year after the start of the pandemic, there seems to be cautious hope for its control and vaccination programs. However, there is still an urgent need for effective drug therapy to prevent severe diseases and limit the long-term complications of COVID-19. We believe that effective drug therapy may require a variety of methods, including early antiviral treatment to prevent virus replication, immunomodulatory treatment to deal with the late high inflammatory state and anticoagulation to prevent the sequelae of venous thromboembolism and micro-thrombosis. In this paper, the characteristics of innate and adaptive immunity induced by SARS-CoV-2 are reviewed, and the current treatment strategies are summarized in detail.

Importantly, with the continuous in-depth study, a lot of research reports have displayed that age, sex and heredity were also risk factors for severe COVID-19 [39, 172] . Firstly, there is little possibility for the older to develop a coordinated adaptive immune response to SARS-CoV-2 than the young people [44] . T cell response against virus infection is determined by the repertoire of naive T cells, which will be declined substantially with age [173] . Compared with 20-year-olds, 65-year-olds in the United States have a 90-fold higher risk of COVID-19 death, as well as 75-year-olds have a 200-fold higher risk of death. Secondly, men with severe COVID-19 have slightly higher risk than that in women due to sex differences in immune responses, although no obvious functional differences have been found in the adaptive immune response [174] . However, in some studies, men infected with SARS-CoV-2 produced higher antibody titer [175] . Interestingly, 10% of the severe COVID-19 patients were IFN-I auto-antibodies, while among them more than 90% were male [176] . Therefore, severe gender differences in COVID-19 can be attributed to differences in innate immune response of IFN-I. Lastly, early genomic and transcriptome studies exhibited that a gene cluster on chromosome 3 was considered as a genetic susceptibility locus in patients with respiratory failure [177] . The immune-related genes loci on chromosome 3 consist of CCR1, CCR2, CCR9, XCR1 and CXCR6. Among them, CCR1 is identified as a receptor of several chemokines (CCL3, 5, 7 and CCL23) [178] . In addition, CCR1 deficient mice could be conducive to the protection of this receptor against excessive inflammation and reduce susceptibility to viruses and fungi [179] .

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Properties of Coronavirus and SARS-CoV-2

Human Coronavirus: Host-Pathogen Interaction

Identification of a new human coronavirus

Characteristics of SARS-CoV-2 and COVID-19

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

SARS-CoV-2 infection-induced immune responses: Friends or foes?

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

The protein expression profile of ACE2 in human tissues

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells

Interaction network of SARS-CoV-2 with host receptome through spike protein

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

Kidney injury molecule-1 is a potential receptor for SARS-CoV-2

Transferrin receptor is another receptor for SARS-CoV-2 entry

Does the SARS-CoV-2 Spike Protein Receptor Binding Domain Interact Effectively with the DPP4 (CD26) Receptor? A Molecular Docking Study

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection

DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Neuropilin-1 is a host factor for SARS-CoV-2 infection

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin

Proteolytic Cleavage of the SARS-CoV-2

Spike Protein and the Role of the Novel S1/S2 Site. iScience

Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

In vitro production of synthetic viral RNAs and their delivery into mammalian cells and the application of viral RNAs in the study of innate interferon responses

Collaboration of Toll-like and RIG-I-like receptors in human dendritic cells: tRIGgering antiviral innate immune responses

COVID-19 pathophysiology: A review

Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19

A distinct innate immune signature marks progression from mild to severe COVID-19

SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19

Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings

Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets

Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia

Adaptive immunity to SARS-CoV-2 and COVID-19

Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease

Comprehensive mapping of immune perturbations associated with severe COVID-19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Helper Cell Biology: A Decade of Discovery and Diseases

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells

Antibody responses to SARS-CoV-2 in patients with COVID-19

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Lessons for COVID-19 Immunity from Other Coronavirus Infections

Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns

Dysregulation of type I interferon responses in COVID-19

The trinity of COVID-19: immunity, inflammation and intervention

Immune determinants of COVID-19 disease presentation and severity

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19

The signal pathways and treatment of cytokine storm in COVID-19

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Activation and evasion of type I interferon responses by SARS-CoV-2

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles

Evasion of Type I Interferon by SARS-CoV-2

A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

Coronavirus virulence genes with main focus on SARS-CoV envelope gene

In vitro reconstitution of SARS-coronavirus mRNA cap methylation

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta

SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO

SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling

SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2

Treatment of SARS-CoV-2: How far have we reached?

Candidate drugs against SARS-CoV-2 and COVID-19

An Update on Current Therapeutic Drugs Treating COVID-19

Favipiravir use for SARS CoV-2 infection

Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)

Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

Early experience with remdesivir in SARS-CoV-2 pneumonia

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity

Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19

Targeting TMPRSS2 in SARS-CoV-2 Infection

Systematic approaches towards the development of host-directed antiviral therapeutics

Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Potential therapeutic and pharmacological strategies for SARS-CoV2

Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19

Baricitinib restrains the immune dysregulation in patients with severe COVID-19

Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs

The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future

SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?

Renin-angiotensin-aldosterone system dysregulation and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) -Is there any scientific evidence for controversy?

SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus

Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study

Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study

Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Antiantibodies, immunoglobulins, and corticosteroids

Role of monoclonal antibody drugs in the treatment of COVID-19

Pharmaco-Immunomodulatory Therapy in COVID-19

Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Anakinra for severe forms of COVID-19: a cohort study

Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study

N-Acetylcysteine to Combat COVID-19: An Evidence Review

The potential mechanism of N-acetylcysteine in treating COVID-19

Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials

N-acetylcysteine (NAC) and Hydrogen Sulfide (H(2)S) in Coronavirus Disease 2019 (COVID-19)

A potential therapeutic agent for SARS-CoV-2

COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2

N-acetylcysteine as a potential treatment for COVID-19

Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins

Clinical performance of different SARS-CoV-2 IgG antibody tests

High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects

The Pathogenesis and Treatment of COVID-19: A System Review

Structures of Human Antibodies Bound to SARS-CoV

Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects

Interplay between SARS-CoV-2 and the type I interferon response

Type I interferon: From innate response to treatment for COVID-19

Inhibition of SARS-CoV-2 by type I and type III interferons

Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases

SARS-CoV-2 infection and stem cells: Interaction and intervention

Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients

Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises

Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

Can mesenchymal stem cell therapy be the interim management of COVID-19?

Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use

Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential

What we have to know about corticosteroids use during Sars-Cov-2 infection

Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2

Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease

Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection

Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study

Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

SARS-CoV-2 infection and thrombotic complications: a narrative review

Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm

Association of coagulation disturbances with severity of COVID-19: a longitudinal study

COVID-19 and the human innate immune system

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Genetic mechanisms of critical illness in Covid-19

The authors have declared that no competing interest exists.